AlphaMaven AlphaMaven

Why 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London event

Reported by Fiercebiotech
Nov 17, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • The original Fierce Biotech article could not be retrieved; the available material is limited to its headline, event listings, and a related 2024 PitchBook report on European venture capital.
  • • The headline frames 2027 as a possible "Europe's year to shine" for biotech funding, based on a panel debate at Fierce's London event.
  • • A PitchBook report cited in the supplemental material described a recovering but uneven European VC environment, with rate cuts and rising median deal sizes offset by lofty AI valuations and a rising share of down rounds.
  • • Medicxi co-founder Francesco De Rubertis argued that biotech venture-led innovation is most prolific when public markets and the macro backdrop are tougher.
Summary
Fierce Biotech's headline, "Why 2027 could be 'Europe's year to shine'," indicates that panelists at its London event debated the outlook for biotech funding in Europe. The full article text could not be retrieved, so the discussion's specific conclusions and speakers are not available here. The event is part of London Life Sciences Week and covers funding trends, business development, and AI in drug discovery.

The supplemental material draws on a PitchBook report, which focuses on European valuations broadly rather than life sciences alone. PitchBook identified three pillars shaping the European VC landscape: rates, recovery, and rationalization. It noted that the European Central Bank and the Bank of England had recently cut rates, and it expected a recovery to continue if further cuts follow. It said valuation rationalization was "less clear," citing lofty price tags in areas such as artificial intelligence.

PitchBook reported that median deal sizes "continued to tick higher across all stages" in the first half of the year, with AI buoying dispersion between early and late stages. The proportion of down rounds in Europe trended upward over the same period, with the U.K. accounting for 83.7% of European down rounds, followed by the Nordic countries.

For context, Forbion raised 1.35 billion euros in April 2023 across two funds, and BGV raised 140 million euros in July 2023. Francesco De Rubertis of Medicxi told Fierce Biotech that biotech venture-led innovation is most prolific when public markets and the macro environment are tougher. These figures and remarks date from 2023 and 2024 and should not be read as current conditions for 2026.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Fiercebiotech Why 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London event